Method of using estrogen-related receptor gamma (ERRγ) status to determine prognosis and treatment strategy for breast cancer, method of using ERRγ as a therapeutic target for treating breast cancer, method of using ERRγ to diagnose breast cancer, and method of using ERRγ to identify individuals predisposed to breast cancer
US7354713B2 · kind B2 · utility
7Cited by
1References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 3, 2003 |
| Grant date | Apr 8, 2008 |
| Priority date | — |
| Expiry date | Jan 13, 2026 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/00
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides that ERRγ is both a breast cancer biomarker and a breast cancer treatment target. A high ERRγ level in breast cancer cells indicates good prognosis. A high level of ERRγ in breast tissue suspected of being cancerous is indicative of breast cancer. Analyzing ERRγ status and optionally along with the status of ERα can help breast cancer patients make treatment choices. Furthermore, breast cancer can be treated by decreasing ERRγ activity in breast cancer cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.